HIV prevention network coordinating center
HIV Prevention Trials Network Leadership and Operations Center
['FUNDING_OTHER'] · FAMILY HEALTH INTERNATIONAL · NIH-11466551
This program runs and supports studies of new long-acting HIV prevention medicines and combined products for people at risk, including young adults, men who have sex with men, transgender women, sex workers, and people who inject drugs.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | FAMILY HEALTH INTERNATIONAL (nih funded) |
| Locations | 1 site (DURHAM, UNITED STATES) |
| Trial ID | NIH-11466551 on ClinicalTrials.gov |
What this research studies
From a patient perspective, this program designs and runs clinical studies to find HIV prevention options that are safe, acceptable, and easy to use. It focuses on long-acting antiretroviral approaches for PrEP, multipurpose products that may also prevent pregnancy or other STIs, and antibody-based strategies. The network works with clinical sites in the U.S. and around the world, including sub-Saharan Africa, and partners with other HIV research groups. If invited, you would visit a participating clinic where staff would explain the prevention product, study procedures, and safety monitoring.
Who could benefit from this research
Good fit: Ideal participants are HIV-negative people at higher risk for HIV—for example sexually active young adults, men who have sex with men, transgender women, female sex workers, people who inject drugs, and women in high-incidence regions—who can attend a participating clinic.
Not a fit: People already living with HIV or those not at risk for HIV are not the primary focus and are unlikely to benefit from these prevention studies.
Why it matters
Potential benefit: If successful, the work could deliver longer-lasting, more convenient HIV prevention options and combined products that reduce HIV and other risks.
How similar studies have performed: Earlier prevention efforts like daily oral PrEP and long-acting injectable cabotegravir have shown clear protection, while multipurpose products and some antibody approaches are newer and less proven.
Where this research is happening
DURHAM, UNITED STATES
- FAMILY HEALTH INTERNATIONAL — DURHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LANDOVITZ, RAPHAEL J — FAMILY HEALTH INTERNATIONAL
- Study coordinator: LANDOVITZ, RAPHAEL J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus